📊 CALC Key Takeaways
Is CalciMedica, Inc. (CALC) a Good Investment?
CalciMedica exhibits critical financial distress with negative stockholders equity (-$1.1M), minimal revenue ($106K, declining -29.7% YoY), and unsustainable operating losses (-$5.6M) representing a cash burn of 5,293% of revenue. The company's apparent profitability ($5.0M net income) is illusory, driven entirely by non-operating gains while core operations hemorrhage cash at -$4.9M annually, providing only ~1.7 years of runway from the current $8.2M cash position.
CalciMedica’s fundamentals are extremely weak: revenue is small and declining, while operating losses, net losses, and free cash outflow are vastly larger than the top line. Although liquidity is currently supported by a solid cash balance and strong current ratio, negative equity and sustained cash burn indicate a fragile financial position that likely depends on future external funding rather than internally generated business strength.
CalciMedica, Inc. Key Strengths (CALC)
- Cash position of $8.2M provides near-term operational runway
- Minimal capital expenditure requirements preserve liquidity for R&D deployment
- Active insider engagement evidenced by 6 Form 4 filings in 90 days
- Cash and equivalents of $11.52M provide near-term liquidity support
- Current and quick ratios of 3.58x indicate acceptable short-term balance sheet liquidity
- Capital expenditure is minimal, limiting additional fixed-asset cash demands
CALC Stock Risks: CalciMedica, Inc. Investment Risks
- Negative stockholders equity (-$1.1M) indicates technical insolvency and balance sheet deterioration
- Unsustainable operating cash burn of $4.9M annually with only $106K revenue generation
- Revenue declining YoY in pharmaceutical sector suggests inability to commercialize products or market traction failure
- Operating losses of 5,293% of revenue indicate fundamental business model failure at current scale
- Cash runway exhaustion within 1.7 years without external funding or operational inflection
- Revenue declined 29.7% YoY and remains far too small to support the cost structure
- Net loss of $29.56M and free cash flow of -$21.21M reflect severe ongoing cash burn
- Negative stockholders’ equity of -$6.64M signals balance-sheet weakness and potential future financing pressure
Key Metrics to Watch
- Operating cash burn trend and path to cash flow breakeven
- Revenue growth from product commercialization or partnerships
- Cash position and dilutive financing events required to extend runway
- Operating margin improvement trajectory toward profitability
- Quarterly operating cash burn relative to cash balance
- Revenue trajectory and whether operating losses narrow materially
CalciMedica, Inc. (CALC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
CalciMedica, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CALC Profit Margin, ROE & Profitability Analysis
CALC vs Healthcare Sector: How CalciMedica, Inc. Compares
How CalciMedica, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CalciMedica, Inc. Stock Overvalued? CALC Valuation Analysis 2026
Based on fundamental analysis, CalciMedica, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CalciMedica, Inc. Balance Sheet: CALC Debt, Cash & Liquidity
CALC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CalciMedica, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
CALC Revenue Growth, EPS Growth & YoY Performance
CalciMedica, Inc. Dividends, Buybacks & Capital Allocation
CALC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CalciMedica, Inc. (CIK: 0001534133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CALC
What is the AI rating for CALC?
CalciMedica, Inc. (CALC) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CALC's key strengths?
Claude: Cash position of $8.2M provides near-term operational runway. Minimal capital expenditure requirements preserve liquidity for R&D deployment. ChatGPT: Cash and equivalents of $11.52M provide near-term liquidity support. Current and quick ratios of 3.58x indicate acceptable short-term balance sheet liquidity.
What are the risks of investing in CALC?
Claude: Negative stockholders equity (-$1.1M) indicates technical insolvency and balance sheet deterioration. Unsustainable operating cash burn of $4.9M annually with only $106K revenue generation. ChatGPT: Revenue declined 29.7% YoY and remains far too small to support the cost structure. Net loss of $29.56M and free cash flow of -$21.21M reflect severe ongoing cash burn.
What is CALC's revenue and growth?
CalciMedica, Inc. reported revenue of $106.0K.
Does CALC pay dividends?
CalciMedica, Inc. does not currently pay dividends.
Where can I find CALC SEC filings?
Official SEC filings for CalciMedica, Inc. (CIK: 0001534133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CALC's EPS?
CalciMedica, Inc. has a diluted EPS of $0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CALC's fundamental grade?
Based on our AI fundamental analysis in June 2026, CalciMedica, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CALC stock overvalued or undervalued?
Valuation metrics for CALC: ROE of N/A (sector avg: 15%), net margin of 4,694.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CALC's AI grade for 2026?
Our dual AI analysis gives CalciMedica, Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CALC's free cash flow?
CalciMedica, Inc.'s operating cash flow is $-4.9M, with capital expenditures of $0.0. FCF margin is -4,581.1%.
How does CALC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4,694.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.61 (avg: 2).